Patent ID: 9675642
Date: 2017-06-13
CPC Classifications: A61K,A61P,C07K,C12N,G01N

Claim:
1. In vitro engineered dendritic cells for prevention of tumor progression in a mammal, the cells comprising a vector comprising a polynucleotide sequence at least 95% identical to SEQ ID NO:13, wherein the polynucleotide sequence encodes a gene switch, said gene switch comprising: (1) (a) a first transcription factor sequence encoding a VP-16 transactivation domain and a chimeric RXR ligand binding domain, and (b) a second transcription factor sequence encoding a GAL4 DNA-binding domain and a (2) a first polynucleotide encoding a polypeptide at least 85% identical to SEQ ID NO: 7, and a second polynucleotide encoding a polypeptide at least 85% identical to SEQ ID NO: 8, the first and second polynucleotides operably linked to a promoter and response element which are activated by said ligand-dependent transcription factor complex, wherein the response element comprises a GAL4-binding site.